JP Morgan
TD Cowen, JP Morgan Initiate Coverage of Tempus AI With Buy, Overweight Ratings
Cowen said that Tempus is a differentiated oncology diagnostics company with an order backlog from pharma clients and the potential for strong growth and rising margins.
Top Five Articles on 360Dx Last Week: Cepheid's Expanded FDA Clearance, JP Morgan Conference, More
Last week, readers were most interested in a story about the FDA issuing clearance with CLIA waiver to Cepheid's Xpert Xpress Multiplex Vaginal Panel.
Top Five Articles on 360Dx Last Week: JP Morgan Healthcare Conference, Cue Health Layoffs, More
Last week, readers were most interested in a story about presentations by Danaher, Abbott, and others at the 42nd JP Morgan Healthcare Conference.
JP Morgan Healthcare Conference, Day 3: Grail, Myriad Genetics, Bio-Techne, Quanterix
Highlights from Day 3 included an update on Grail, thoughts by Bio-Techne's incoming CEO on the company, and Quanterix’s corporate reorganization.
JP Morgan Healthcare Conference, Day 2: Danaher, Abbott, Thermo Fisher Scientific, Revvity, More
Highlights from the second day of the conference included updates on Danaher's Cepheid business and Revvity's China business.
Dec 30, 2022
Top 10 Articles on 360Dx in 2022
Sep 8, 2022
Morgan Health Invests $20M in LetsGetChecked
Aug 25, 2021
PerkinElmer Reaches Deal for $1.5B Credit Facility
Aug 12, 2021